PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker
China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.
PODCAST: Corruption at a major policy bank, and AbbVie sues an upstart drug maker
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
RELATED ARTICLES
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK -
Chinese securities regulator puts lid on Hong Kong IPO tea party
2150.HK 2555.HK
-
Modern China Tea Shop fights the flow with traditional flavors, directly operated stores
2150.HK
- Green Tea brews up IPO-funded small-town expansion plan
- Mixue brews up renewed IPO bid, tempting investors with overseas expansion
- Guming joins China’s tea market party with IPO bid
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
